Volume 21: Issue 5 (Dec 2022): Primary and Secondary Glomerular Diseases

Glassock RJ, Fervenza FC, Hebert L, Cameron JS: Nephrotic syndrome redux. Nephrol Dial Transplant 30: 12–17, 2015 PubMed

• PubMed
Glassock RJ, Fervenza FC, Hebert L, Cameron JS: Nephrotic syndrome redux. Nephrol Dial Transplant 30: 12–17, 2015 PubMed)| false
• Search Google Scholar
• Export Citation

van de Logt AE, Rijpma SR, Vink CH, Prudon-Rosmulder E, Wetzels JF, van Berkel M: The bias between different albumin assays may affect clinical decision-making. Kidney Int 95: 1514–1517, 2019 PubMed

• PubMed
van de Logt AE, Rijpma SR, Vink CH, Prudon-Rosmulder E, Wetzels JF, van Berkel M: The bias between different albumin assays may affect clinical decision-making. Kidney Int 95: 1514–1517, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Meyrier A, Niaudet P: Acute kidney injury complicating nephrotic syndrome of minimal change disease. Kidney Int 94: 861–869, 2018 PubMed

• PubMed
Meyrier A, Niaudet P: Acute kidney injury complicating nephrotic syndrome of minimal change disease. Kidney Int 94: 861–869, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Glassock RJ: Secondary minimal change disease. Nephrol Dial Transplant 18[Suppl 6]: vi52–vi58, 2003 PubMed

• PubMed
Glassock RJ: Secondary minimal change disease. Nephrol Dial Transplant 18[Suppl 6]: vi52–vi58, 2003 PubMed)| false
• Search Google Scholar
• Export Citation

Shalhoub RJ: Pathogenesis of lipoid nephrosis: A disorder of T-cell function. Lancet 2: 556–560, 1974 PubMed

• PubMed
Shalhoub RJ: Pathogenesis of lipoid nephrosis: A disorder of T-cell function. Lancet 2: 556–560, 1974 PubMed)| false
• Search Google Scholar
• Export Citation

Lagrue G, Xheneumont S, Branellec A, Hirbec G, Weil B: A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome. Biomedicine (Paris) 23: 37–40, 1975 PubMed

• PubMed
Lagrue G, Xheneumont S, Branellec A, Hirbec G, Weil B: A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome. Biomedicine (Paris) 23: 37–40, 1975 PubMed)| false
• Search Google Scholar
• Export Citation

Heslan JM, Branellec AI, Pilatte Y, Lang P, Lagrue G: Differentiation between vascular permeability factor and IL-2 in lymphocyte supernatants from patients with minimal-change nephrotic syndrome. Clin Exp Immunol 86: 157–162, 1991 PubMed

• PubMed
Heslan JM, Branellec AI, Pilatte Y, Lang P, Lagrue G: Differentiation between vascular permeability factor and IL-2 in lymphocyte supernatants from patients with minimal-change nephrotic syndrome. Clin Exp Immunol 86: 157–162, 1991 PubMed)| false
• Search Google Scholar
• Export Citation

Cheung PK, Stulp B, Immenschuh S, Borghuis T, Baller JF, Bakker WW: Is 100KF an isoform of hemopexin? Immunochemical characterization of the vasoactive plasma factor 100KF. J Am Soc Nephrol 10: 1700–1708, 1999 PubMed

• PubMed
Cheung PK, Stulp B, Immenschuh S, Borghuis T, Baller JF, Bakker WW: Is 100KF an isoform of hemopexin? Immunochemical characterization of the vasoactive plasma factor 100KF. J Am Soc Nephrol 10: 1700–1708, 1999 PubMed)| false
• Search Google Scholar
• Export Citation

Cheung PK, Klok PA, Baller JF, Bakker WW: Induction of experimental proteinuria in vivo following infusion of human plasma hemopexin. Kidney Int 57: 1512–1520, 2000 PubMed

• PubMed
Cheung PK, Klok PA, Baller JF, Bakker WW: Induction of experimental proteinuria in vivo following infusion of human plasma hemopexin. Kidney Int 57: 1512–1520, 2000 PubMed)| false
• Search Google Scholar
• Export Citation

Clement LC, Avila-Casado C, Macé C, Soria E, Bakker WW, Kersten S, et al.: Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 17: 117–122, 2011 PubMed

• PubMed
Clement LC, Avila-Casado C, Macé C, Soria E, Bakker WW, Kersten S, : Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 17: 117–122, 2011 PubMed)| false
• Search Google Scholar
• Export Citation

Lai KW, Wei CL, Tan LK, Tan PH, Chiang GS, Lee CG, et al.: Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol 18: 1476–1485, 2007 PubMed

• PubMed
Lai KW, Wei CL, Tan LK, Tan PH, Chiang GS, Lee CG, : Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol 18: 1476–1485, 2007 PubMed)| false
• Search Google Scholar
• Export Citation

Chugh SS, Clement LC, Macé C: New insights into human minimal change disease: Lessons from animal models. Am J Kidney Dis 59: 284–292, 2012 PubMed

• PubMed
Chugh SS, Clement LC, Macé C: New insights into human minimal change disease: Lessons from animal models. Am J Kidney Dis 59: 284–292, 2012 PubMed)| false
• Search Google Scholar
• Export Citation

Garin EH, Blanchard DK, Matsushima K, Djeu JY: IL-8 production by peripheral blood mononuclear cells in nephrotic patients. Kidney Int 45: 1311–1317, 1994 PubMed

• PubMed
Garin EH, Blanchard DK, Matsushima K, Djeu JY: IL-8 production by peripheral blood mononuclear cells in nephrotic patients. Kidney Int 45: 1311–1317, 1994 PubMed)| false
• Search Google Scholar
• Export Citation

Kondo S, Yoshizawa N, Kusumi Y, Takeuchi A, Torikata C: Studies of glomerular permeability factor (GPF) in focal segmental glomerular sclerosis and the relationship between GPF and vascular permeability factor (VPF). Clin Nephrol 52: 278–284, 1999 PubMed

• PubMed
Kondo S, Yoshizawa N, Kusumi Y, Takeuchi A, Torikata C: Studies of glomerular permeability factor (GPF) in focal segmental glomerular sclerosis and the relationship between GPF and vascular permeability factor (VPF). Clin Nephrol 52: 278–284, 1999 PubMed)| false
• Search Google Scholar
• Export Citation

Clement LC, Macé C, Avila-Casado C, Joles JA, Kersten S, Chugh SS: Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med 20: 37–46, 2014 PubMed

• PubMed
Clement LC, Macé C, Avila-Casado C, Joles JA, Kersten S, Chugh SS: Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med 20: 37–46, 2014 PubMed)| false
• Search Google Scholar
• Export Citation

Kim AH, Chung JJ, Akilesh S, Koziell A, Jain S, Hodgin JB, et al.: B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement. JCI Insight 2: e81836, 2017 PubMed

• PubMed
Kim AH, Chung JJ, Akilesh S, Koziell A, Jain S, Hodgin JB, : B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement. JCI Insight 2: e81836, 2017 PubMed)| false
• Search Google Scholar
• Export Citation

Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang SY, Henique C, et al.: NEPHRUTIX: A randomized, double-blind, placebo vs rituximab-controlled trial assessing T-cell subset changes in minimal change nephrotic syndrome. J Autoimmun 88: 91–102, 2018 PubMed

• PubMed
Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang SY, Henique C, : NEPHRUTIX: A randomized, double-blind, placebo vs rituximab-controlled trial assessing T-cell subset changes in minimal change nephrotic syndrome. J Autoimmun 88: 91–102, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Watts AJB, Keller KH, Lerner G, Rosales I, Collins AB, Sekulic M, et al.: Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol 33: 238–252, 2022 PubMed

• PubMed
Watts AJB, Keller KH, Lerner G, Rosales I, Collins AB, Sekulic M, : Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol 33: 238–252, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Yoshikawa N, Nakanishi K, Sako M, Oba MS, Mori R, Ota E, et al.; Japanese Study Group of Kidney Disease in Children: A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int 87: 225–232, 2015 PubMed

• PubMed
Yoshikawa N, Nakanishi K, Sako M, Oba MS, Mori R, Ota E, ; Japanese Study Group of Kidney Disease in Children: A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int 87: 225–232, 2015 PubMed)| false
• Search Google Scholar
• Export Citation

Sinha A, Saha A, Kumar M, Sharma S, Afzal K, Mehta A, et al.: Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. Kidney Int 87: 217–224, 2015 PubMed

• PubMed
Sinha A, Saha A, Kumar M, Sharma S, Afzal K, Mehta A, : Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. Kidney Int 87: 217–224, 2015 PubMed)| false
• Search Google Scholar
• Export Citation

Webb NJA, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, et al.; PREDNOS Collaborative Group: Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: Phase III randomised controlled trial and economic evaluation. BMJ 365: l1800, 2019 PubMed

• PubMed
Webb NJA, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, ; PREDNOS Collaborative Group: Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: Phase III randomised controlled trial and economic evaluation. BMJ 365: l1800, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Hahn D, Hodson EM, Willis NS, Craig JC: Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev (3): CD001533, 2015 PubMed

• PubMed
Hahn D, Hodson EM, Willis NS, Craig JC: Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev (3): CD001533, 2015 PubMed)| false
• Search Google Scholar
• Export Citation

Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, et al.: Adult minimal-change disease: Clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2: 445–453, 2007 PubMed

• PubMed
Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, : Adult minimal-change disease: Clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2: 445–453, 2007 PubMed)| false
• Search Google Scholar
• Export Citation

Li H, Shi X, Shen H, Li X, Wang H, Li H, et al.: Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: A multicenter, open-label, nonrandomized cohort trial. Clin Ther 34: 1112–1120, 2012 PubMed

• PubMed
Li H, Shi X, Shen H, Li X, Wang H, Li H, : Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: A multicenter, open-label, nonrandomized cohort trial. Clin Ther 34: 1112–1120, 2012 PubMed)| false
• Search Google Scholar
• Export Citation

Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, et al.: Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: A multicentre randomized controlled trial. Nephrol Dial Transplant 8: 1326–1332, 1993 PubMed

• PubMed
Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, : Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: A multicentre randomized controlled trial. Nephrol Dial Transplant 8: 1326–1332, 1993 PubMed)| false
• Search Google Scholar
• Export Citation

Li X, Li H, Chen J, He Q, Lv R, Lin W, et al.: Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome. Nephrol Dial Transplant 23: 1919–1925, 2008 PubMed

• PubMed
Li X, Li H, Chen J, He Q, Lv R, Lin W, : Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome. Nephrol Dial Transplant 23: 1919–1925, 2008 PubMed)| false
• Search Google Scholar
• Export Citation

Meyrier A, Condamin MC, Broneer D; Collaborative Group of the French Society of Nephrology: Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: Minimal-change disease and focal-segmental glomerulosclerosis. Clin Nephrol 35[Suppl 1]: S37–S42, 1991 PubMed

• PubMed
Meyrier A, Condamin MC, Broneer D; Collaborative Group of the French Society of Nephrology: Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: Minimal-change disease and focal-segmental glomerulosclerosis. Clin Nephrol 35[Suppl 1]: S37–S42, 1991 PubMed)| false
• Search Google Scholar
• Export Citation

Li X, Liu Z, Wang L, Wang R, Ding G, Shi W, et al.: Tacrolimus monotherapy after intravenous methylprednisolone in adults with minimal change nephrotic syndrome. J Am Soc Nephrol 28: 1286–1295, 2017 PubMed

• PubMed
Li X, Liu Z, Wang L, Wang R, Ding G, Shi W, : Tacrolimus monotherapy after intravenous methylprednisolone in adults with minimal change nephrotic syndrome. J Am Soc Nephrol 28: 1286–1295, 2017 PubMed)| false
• Search Google Scholar
• Export Citation

Medjeral-Thomas NR, Lawrence C, Condon M, Sood B, Warwicker P, Brown H, et al.: Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: A multicenter, randomized, controlled trial. Clin J Am Soc Nephrol 15: 209–218, 2020 PubMed

• PubMed
Medjeral-Thomas NR, Lawrence C, Condon M, Sood B, Warwicker P, Brown H, : Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: A multicenter, randomized, controlled trial. Clin J Am Soc Nephrol 15: 209–218, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Gellermann J, Weber L, Pape L, Tönshoff B, Hoyer P, Querfeld U; Gesellschaft für Pädiatrische Nephrologie (GPN): Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 24: 1689–1697, 2013 PubMed

• PubMed
Gellermann J, Weber L, Pape L, Tönshoff B, Hoyer P, Querfeld U; Gesellschaft für Pädiatrische Nephrologie (GPN): Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 24: 1689–1697, 2013 PubMed)| false
• Search Google Scholar
• Export Citation

Geng HY, Ji LN, Chen CY, Tu J, Li HR, Bao R, et al.: [Mycophenolate mofetil versus cyclosporine A in children with primary refractory nephrotic syndrome]. Zhonghua Er Ke Za Zhi 56: 651–656, 2018 PubMed

• PubMed
Geng HY, Ji LN, Chen CY, Tu J, Li HR, Bao R, : [Mycophenolate mofetil versus cyclosporine A in children with primary refractory nephrotic syndrome]. Zhonghua Er Ke Za Zhi 56: 651–656, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Sinha A, Puraswani M, Kalaivani M, Goyal P, Hari P, Bagga A: Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: An open-label randomized controlled trial. Kidney Int 95: 210–218, 2019 PubMed

• PubMed
Sinha A, Puraswani M, Kalaivani M, Goyal P, Hari P, Bagga A: Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: An open-label randomized controlled trial. Kidney Int 95: 210–218, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Rémy P, Audard V, Natella PA, Pelle G, Dussol B, Leray-Moragues H, et al.; MSN Trial Investigators: An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN study). Kidney Int 94: 1217–1226, 2018 PubMed

• PubMed
Rémy P, Audard V, Natella PA, Pelle G, Dussol B, Leray-Moragues H, ; MSN Trial Investigators: An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN study). Kidney Int 94: 1217–1226, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Benz K, Dötsch J, Rascher W, Stachel D: Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19: 794–797, 2004 PubMed

• PubMed
Benz K, Dötsch J, Rascher W, Stachel D: Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19: 794–797, 2004 PubMed)| false
• Search Google Scholar
• Export Citation

Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, et al.: Rituximab in children with steroid-dependent nephrotic syndrome: A multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26: 2259–2266, 2015 PubMed

• PubMed
Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, : Rituximab in children with steroid-dependent nephrotic syndrome: A multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26: 2259–2266, 2015 PubMed)| false
• Search Google Scholar
• Export Citation

Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, et al.; Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group: Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: A multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384: 1273–1281, 2014 PubMed

• PubMed
Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, ; Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group: Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: A multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384: 1273–1281, 2014 PubMed)| false
• Search Google Scholar
• Export Citation

Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasà M, et al.; Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group: Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 25: 850–863, 2014 PubMed

• PubMed
Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasà M, ; Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group: Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 25: 850–863, 2014 PubMed)| false
• Search Google Scholar
• Export Citation

Webb H, Jaureguiberry G, Dufek S, Tullus K, Bockenhauer D: Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome. Pediatr Nephrol 31: 589–594, 2016 PubMed

• PubMed
Webb H, Jaureguiberry G, Dufek S, Tullus K, Bockenhauer D: Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome. Pediatr Nephrol 31: 589–594, 2016 PubMed)| false
• Search Google Scholar
• Export Citation

Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, et al.: Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: A randomized clinical trial. JAMA Pediatr 172: 757–764, 2018 PubMed

• PubMed
Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, : Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: A randomized clinical trial. JAMA Pediatr 172: 757–764, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Hogan J, Dossier C, Kwon T, Macher MA, Maisin A, Couderc A, et al.: Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 34: 253–259, 2019 PubMed

• PubMed
Hogan J, Dossier C, Kwon T, Macher MA, Maisin A, Couderc A, : Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 34: 253–259, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL, et al.: Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 97: 393–401, 2020 PubMed

• PubMed
Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL, : Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 97: 393–401, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, et al.: Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: A randomized controlled trial. Clin J Am Soc Nephrol 6: 1308–1315, 2011 PubMed

• PubMed
Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, : Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: A randomized controlled trial. Clin J Am Soc Nephrol 6: 1308–1315, 2011 PubMed)| false
• Search Google Scholar
• Export Citation

Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, et al.: Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 84: 1025–1033, 2013 PubMed

• PubMed
Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, : Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 84: 1025–1033, 2013 PubMed)| false
• Search Google Scholar
• Export Citation

Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, et al.: Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 23: 1117–1124, 2012 PubMed

• PubMed
Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, : Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 23: 1117–1124, 2012 PubMed)| false
• Search Google Scholar
• Export Citation

Ravani P, Bonanni A, Ghiggeri GM: Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: Study protocol. BMJ Open 7: e013319, 2017 PubMed

• PubMed
Ravani P, Bonanni A, Ghiggeri GM: Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: Study protocol. BMJ Open 7: e013319, 2017 PubMed)| false
• Search Google Scholar
• Export Citation

Iwabuchi Y, Miyabe Y, Makabe S, Nakano M, Manabe S, Karasawa K, et al.: Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease. Medicine (Baltimore) 97: e12704, 2018 PubMed

• PubMed
Iwabuchi Y, Miyabe Y, Makabe S, Nakano M, Manabe S, Karasawa K, : Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease. Medicine (Baltimore) 97: e12704, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Fenoglio R, Sciascia S, Beltrame G, Mesiano P, Ferro M, Quattrocchio G, et al.: Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget 9: 28799–28804, 2018 PubMed

• PubMed
Fenoglio R, Sciascia S, Beltrame G, Mesiano P, Ferro M, Quattrocchio G, : Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget 9: 28799–28804, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G, Hoxha E, Kurschat CE, Busch M, et al.: Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: A systematic review. Am J Nephrol 39: 322–330, 2014 PubMed

• PubMed
Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G, Hoxha E, Kurschat CE, Busch M, : Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: A systematic review. Am J Nephrol 39: 322–330, 2014 PubMed)| false
• Search Google Scholar
• Export Citation

Kittanamongkolchai W, Cheungpasitporn W, Zand L: Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: A systematic review and meta-analysis. Clin Kidney J 9: 387–396, 2016 PubMed

• PubMed
Kittanamongkolchai W, Cheungpasitporn W, Zand L: Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: A systematic review and meta-analysis. Clin Kidney J 9: 387–396, 2016 PubMed)| false
• Search Google Scholar
• Export Citation

Madan A, Mijovic-Das S, Stankovic A, Teehan G, Milward AS, Khastgir A: Acthar gel in the treatment of nephrotic syndrome: A multicenter retrospective case series. BMC Nephrol 17: 37, 2016 PubMed

• PubMed
Madan A, Mijovic-Das S, Stankovic A, Teehan G, Milward AS, Khastgir A: Acthar gel in the treatment of nephrotic syndrome: A multicenter retrospective case series. BMC Nephrol 17: 37, 2016 PubMed)| false
• Search Google Scholar
• Export Citation

Wang CS, Travers C, McCracken C, Leong T, Gbadegesin R, Quiroga A, et al.: Adrenocorticotropic hormone for childhood nephrotic syndrome: The ATLANTIS randomized trial. Clin J Am Soc Nephrol 13: 1859–1865, 2018 PubMed

• PubMed
Wang CS, Travers C, McCracken C, Leong T, Gbadegesin R, Quiroga A, : Adrenocorticotropic hormone for childhood nephrotic syndrome: The ATLANTIS randomized trial. Clin J Am Soc Nephrol 13: 1859–1865, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Szeto CC, Lai FM, Chow KM, Kwan BC, Kwong VW, Leung CB, et al.: Long-term outcome of biopsy-proven minimal change nephropathy in Chinese adults. Am J Kidney Dis 65: 710–718, 2015 PubMed

• PubMed
Szeto CC, Lai FM, Chow KM, Kwan BC, Kwong VW, Leung CB, : Long-term outcome of biopsy-proven minimal change nephropathy in Chinese adults. Am J Kidney Dis 65: 710–718, 2015 PubMed)| false
• Search Google Scholar
• Export Citation

Sethi S, Glassock RJ, Fervenza FC: Focal segmental glomerulosclerosis: Towards a better understanding for the practicing nephrologist. Nephrol Dial Transplant 30: 375–384, 2015 PubMed

• PubMed
Sethi S, Glassock RJ, Fervenza FC: Focal segmental glomerulosclerosis: Towards a better understanding for the practicing nephrologist. Nephrol Dial Transplant 30: 375–384, 2015 PubMed)| false
• Search Google Scholar
• Export Citation

Izzedine H, Launay-Vacher V, Bourry E, Brocheriou I, Karie S, Deray G: Drug-induced glomerulopathies. Expert Opin Drug Saf 5: 95–106, 2006 PubMed

• PubMed
Izzedine H, Launay-Vacher V, Bourry E, Brocheriou I, Karie S, Deray G: Drug-induced glomerulopathies. Expert Opin Drug Saf 5: 95–106, 2006 PubMed)| false
• Search Google Scholar
• Export Citation

Chandra P, Kopp JB: Viruses and collapsing glomerulopathy: A brief critical review. Clin Kidney J 6: 1–5, 2013 PubMed

• PubMed
Chandra P, Kopp JB: Viruses and collapsing glomerulopathy: A brief critical review. Clin Kidney J 6: 1–5, 2013 PubMed)| false
• Search Google Scholar
• Export Citation

Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD: Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 59: 1498–1509, 2001 PubMed

• PubMed
Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD: Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 59: 1498–1509, 2001 PubMed)| false
• Search Google Scholar
• Export Citation

Kriz W, Lemley KV: A potential role for mechanical forces in the detachment of podocytes and the progression of CKD. J Am Soc Nephrol 26: 258–269, 2015 PubMed

• PubMed
Kriz W, Lemley KV: A potential role for mechanical forces in the detachment of podocytes and the progression of CKD. J Am Soc Nephrol 26: 258–269, 2015 PubMed)| false
• Search Google Scholar
• Export Citation

Kriz W, Lemley KV: Potential relevance of shear stress for slit diaphragm and podocyte function. Kidney Int 91: 1283–1286, 2017 PubMed

• PubMed
Kriz W, Lemley KV: Potential relevance of shear stress for slit diaphragm and podocyte function. Kidney Int 91: 1283–1286, 2017 PubMed)| false
• Search Google Scholar
• Export Citation

De Vriese AS, Wetzels JF, Glassock RJ, Sethi S, Fervenza FC: Therapeutic trials in adult FSGS: Lessons learned and the road forward. Nat Rev Nephrol 17: 619–630, 2021 PubMed

• PubMed
De Vriese AS, Wetzels JF, Glassock RJ, Sethi S, Fervenza FC: Therapeutic trials in adult FSGS: Lessons learned and the road forward. Nat Rev Nephrol 17: 619–630, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al.: Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 100: 753–779, 2021 PubMed

• PubMed
Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, : Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 100: 753–779, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Campbell KN, Tumlin JA: Protecting podocytes: A key target for therapy of focal segmental glomerulosclerosis. Am J Nephrol 47[Suppl 1]: 14–29, 2018 PubMed

• PubMed
Campbell KN, Tumlin JA: Protecting podocytes: A key target for therapy of focal segmental glomerulosclerosis. Am J Nephrol 47[Suppl 1]: 14–29, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Campbell KN, Wong JS, Gupta R, Asanuma K, Sudol M, He JC, et al.: Yes-associated protein (YAP) promotes cell survival by inhibiting proapoptotic dendrin signaling. J Biol Chem 288: 17057–17062, 2013 PubMed

• PubMed
Campbell KN, Wong JS, Gupta R, Asanuma K, Sudol M, He JC, : Yes-associated protein (YAP) promotes cell survival by inhibiting proapoptotic dendrin signaling. J Biol Chem 288: 17057–17062, 2013 PubMed)| false
• Search Google Scholar
• Export Citation

Schwartzman M, Reginensi A, Wong JS, Basgen JM, Meliambro K, Nicholas SB, et al.: Podocyte-specific deletion of Yes-associated protein causes FSGS and progressive renal failure. J Am Soc Nephrol 27: 216–226, 2016 PubMed

• PubMed
Schwartzman M, Reginensi A, Wong JS, Basgen JM, Meliambro K, Nicholas SB, : Podocyte-specific deletion of Yes-associated protein causes FSGS and progressive renal failure. J Am Soc Nephrol 27: 216–226, 2016 PubMed)| false
• Search Google Scholar
• Export Citation

Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, et al.: Podocyte depletion causes glomerulosclerosis: Diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 16: 2941–2952, 2005 PubMed

• PubMed
Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, : Podocyte depletion causes glomerulosclerosis: Diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 16: 2941–2952, 2005 PubMed)| false
• Search Google Scholar
• Export Citation

Eng DG, Sunseri MW, Kaverina NV, Roeder SS, Pippin JW, Shankland SJ: Glomerular parietal epithelial cells contribute to adult podocyte regeneration in experimental focal segmental glomerulosclerosis. Kidney Int 88: 999–1012, 2015 PubMed

• PubMed
Eng DG, Sunseri MW, Kaverina NV, Roeder SS, Pippin JW, Shankland SJ: Glomerular parietal epithelial cells contribute to adult podocyte regeneration in experimental focal segmental glomerulosclerosis. Kidney Int 88: 999–1012, 2015 PubMed)| false
• Search Google Scholar
• Export Citation

Kretzler M: Role of podocytes in focal sclerosis: Defining the point of no return. J Am Soc Nephrol 16: 2830–2832, 2005 PubMed

• PubMed
Kretzler M: Role of podocytes in focal sclerosis: Defining the point of no return. J Am Soc Nephrol 16: 2830–2832, 2005 PubMed)| false
• Search Google Scholar
• Export Citation

Savin VJ, Sharma M, Zhou J, Gennochi D, Fields T, Sharma R, et al.: Renal and hematological effects of CLCF-1, a B-cell-stimulating cytokine of the IL-6 family. J Immunol Res 2015: 714964, 2015 PubMed

• PubMed
Savin VJ, Sharma M, Zhou J, Gennochi D, Fields T, Sharma R, : Renal and hematological effects of CLCF-1, a B-cell-stimulating cytokine of the IL-6 family. J Immunol Res 2015: 714964, 2015 PubMed)| false
• Search Google Scholar
• Export Citation

Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al.: Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952–960, 2011 PubMed

• PubMed
Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, : Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952–960, 2011 PubMed)| false
• Search Google Scholar
• Export Citation

Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, et al.: A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med 6: 256ra136, 2014 PubMed

• PubMed
Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, : A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med 6: 256ra136, 2014 PubMed)| false
• Search Google Scholar
• Export Citation

Wada T, Nangaku M: A circulating permeability factor in focal segmental glomerulosclerosis: The hunt continues. Clin Kidney J 8: 708–715, 2015 PubMed

• PubMed
Wada T, Nangaku M: A circulating permeability factor in focal segmental glomerulosclerosis: The hunt continues. Clin Kidney J 8: 708–715, 2015 PubMed)| false
• Search Google Scholar
• Export Citation

Lepori N, Zand L, Sethi S, Fernandez-Juarez G, Fervenza FC: Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults. Clin Kidney J 11: 179–190, 2018 PubMed

• PubMed
Lepori N, Zand L, Sethi S, Fernandez-Juarez G, Fervenza FC: Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults. Clin Kidney J 11: 179–190, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

De Vriese AS, Sethi S, Nath KA, Glassock RJ, Fervenza FC: Differentiating primary, genetic, and secondary FSGS in adults: A clinicopathologic approach. J Am Soc Nephrol 29: 759–774, 2018 PubMed

• PubMed
De Vriese AS, Sethi S, Nath KA, Glassock RJ, Fervenza FC: Differentiating primary, genetic, and secondary FSGS in adults: A clinicopathologic approach. J Am Soc Nephrol 29: 759–774, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Buxeda A, Said S, Nasr SH, Soler MJ, Howard MT, Maguire LJ, et al.: Crystal-induced podocytopathy producing collapsing focal segmental glomerulosclerosis in monoclonal gammopathy of renal significance: A case report. Kidney Med 3: 659–664, 2021 PubMed

• PubMed
Buxeda A, Said S, Nasr SH, Soler MJ, Howard MT, Maguire LJ, : Crystal-induced podocytopathy producing collapsing focal segmental glomerulosclerosis in monoclonal gammopathy of renal significance: A case report. Kidney Med 3: 659–664, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Sethi S, Zand L, Nasr SH, Glassock RJ, Fervenza FC: Focal and segmental glomerulosclerosis: Clinical and kidney biopsy correlations. Clin Kidney J 7: 531–537, 2014 PubMed

• PubMed
Sethi S, Zand L, Nasr SH, Glassock RJ, Fervenza FC: Focal and segmental glomerulosclerosis: Clinical and kidney biopsy correlations. Clin Kidney J 7: 531–537, 2014 PubMed)| false
• Search Google Scholar
• Export Citation

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al.; CREDENCE Trial Investigators: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380: 2295–2306, 2019 PubMed

• PubMed
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, ; CREDENCE Trial Investigators: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380: 2295–2306, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

van den Berg JG, van den Bergh Weerman MA, Assmann KJ, Weening JJ, Florquin S: Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 66: 1901–1906, 2004 PubMed

• PubMed
van den Berg JG, van den Bergh Weerman MA, Assmann KJ, Weening JJ, Florquin S: Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 66: 1901–1906, 2004 PubMed)| false
• Search Google Scholar
• Export Citation

Deegens JK, Dijkman HB, Borm GF, Steenbergen EJ, van den Berg JG, Weening JJ, et al.: Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int 74: 1568–1576, 2008 PubMed

• PubMed
Deegens JK, Dijkman HB, Borm GF, Steenbergen EJ, van den Berg JG, Weening JJ, : Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int 74: 1568–1576, 2008 PubMed)| false
• Search Google Scholar
• Export Citation

Maas RJ, Deegens JK, Smeets B, Moeller MJ, Wetzels JF: Minimal change disease and idiopathic FSGS: Manifestations of the same disease. Nat Rev Nephrol 12: 768–776, 2016 PubMed

• PubMed
Maas RJ, Deegens JK, Smeets B, Moeller MJ, Wetzels JF: Minimal change disease and idiopathic FSGS: Manifestations of the same disease. Nat Rev Nephrol 12: 768–776, 2016 PubMed)| false
• Search Google Scholar
• Export Citation

Hommos MS, De Vriese AS, Alexander MP, Sethi S, Vaughan L, Zand L, et al.: The incidence of primary vs secondary focal segmental glomerulosclerosis: A clinicopathologic study. Mayo Clin Proc 92: 1772–1781, 2017 PubMed

• PubMed
Hommos MS, De Vriese AS, Alexander MP, Sethi S, Vaughan L, Zand L, : The incidence of primary vs secondary focal segmental glomerulosclerosis: A clinicopathologic study. Mayo Clin Proc 92: 1772–1781, 2017 PubMed)| false
• Search Google Scholar
• Export Citation

Zand L, Glassock RJ, De Vriese AS, Sethi S, Fervenza FC: What are we missing in the clinical trials of focal segmental glomerulosclerosis? Nephrol Dial Transplant 32[Suppl 1]: i14–i21, 2017 PubMed

• PubMed
Zand L, Glassock RJ, De Vriese AS, Sethi S, Fervenza FC: What are we missing in the clinical trials of focal segmental glomerulosclerosis? Nephrol Dial Transplant 32[Suppl 1]: i14–i21, 2017 PubMed)| false
• Search Google Scholar
• Export Citation

Hogan J, Mohan P, Appel GB: Diagnostic tests and treatment options in glomerular disease: 2014 update. Am J Kidney Dis 63: 656–666, 2014 PubMed